xFOREST Therapeutics Co., Ltd.
Development of Hit to Lead Platform to Accelerate RNA-Targeted Small Molecule Drug Discovery

Program name

Deep-Tech Startups Support Program

Research theme

Development of Hit to Lead Platform to Accelerate RNA-Targeted Small Molecule Drug Discovery

Business Plan

xFOREST is a leading company in the field, providing solutions to pharmaceutical companies specializing in exploratory processes focused on RNA. Through this grant project, we aim to establish a Hit-to-Lead development platform, creating a foundation for generating lead compounds.

Research Outline

This research project aims to establish a Hit-to-Lead development platform to optimize lead compounds from hit compounds.

• [1] Establishing compound optimization methods specialized for RNA-targeted drug discovery and generating lead compounds.
• [2] Developing a binding selectivity evaluation system to predict off-target toxicity.
• [3] Building compound optimization methods through 3D binding mode analysis of RNA-compound interactions.

International collaborative technology demonstration

• Download this page（153KB）